Quick Answer
ORAMED PHARMACEUTICALS INC. reported Net Income Loss of $64.05 million for the year ending 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +436.0% in Net Income Loss from 2024 to 2025.
- This data is from ORAMED PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), ORAMED PHARMACEUTICALS INC.'s Net Income Loss has grown by 2,412.9%.
- Historical annual values: Fiscal year 2025: $64.05 million | Fiscal year 2024: -$19.06 million | Fiscal year 2023: $5.09 million | Fiscal year 2022: -$36.56 million | Fiscal year 2021: -$22.99 million | Fiscal year 2020: -$11.51 million | Fiscal year 2019: -$14.36 million | Fiscal year 2018: -$12.73 million | Fiscal year 2017: -$10.48 million | Fiscal year 2016: -$10.96 million | Fiscal year 2015: -$7.23 million | Fiscal year 2014: -$5.70 million | Fiscal year 2013: $4.23 million | Fiscal year 2012: -$3.34 million | Fiscal year 2011: -$1.56 million | Fiscal year 2010: -$2.98 million | Fiscal year 2009: -$2.76 million | Fiscal year 2008: -$2.77 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: